Dr. Kiran Patil is an accomplished researcher with over a decade of experience in pharmaceuticals and drug delivery systems. His journey began at R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, culminating in a postgraduate degree in 2012. During his Ph.D., he pioneered surface-functionalized gelatin nanoparticles using a quality-by-design approach, revolutionizing drug delivery. Their focus on utilizing these nanoparticles to administer linezolid for tuberculosis treatment underwent rigorous testing, showcasing their commitment to combatting this disease. With expertise in formulating drug delivery systems and an impressive publication record of over 25 research papers in high-impact journals, he is a trailblazer in the field, contributing significantly to advancements in pharmaceutical sciences.
EDUCATION
Ph.D. in Pharmaceutical Sciences
M. Pharmacy in Pharmaceutics
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmacology, Toxicology and Pharmaceutics, Pharmaceutical Science, Drug Discovery
34
Scopus Publications
932
Scholar Citations
14
Scholar h-index
19
Scholar i10-index
Scopus Publications
In-vivo Pharmacokinetic Assessment and In-vitro Characterization of Strategically Optimized Perphenazine-loaded Nanostructured Lipid Carriers for Nose-to-brain Targeting Yogeeta O. Agrawal, Tulshidas S. Patil, Kiran D. Patil, Nayan A. Gujarathi, Amit Gangwal, Sameer N. Goyal Recent Patents on Nanotechnology, 2026 Background: Perphenazine (PPZ) is a prevalent antipsychotic medication used to treat schizophrenia. After oral treatment, however, it shows substantial first-pass metabolism and decreased bioavailability. Objective: The goal of this research was to incorporate PPZ into nanostructured lipid carriers and thereby improve its bioavailability and brain targeting (PPZ-NLCs). Methods: PPZ-NLCs were formulated by a high-pressure homogenization methodology under heated conditions and optimized by applying a 23-full factorial design. Results: The optimized PPZ-NLCs showed particle size 167.5 nm, PDI 0.277, Zeta Potential of -28.8 mV, and 98.6% EE. The drug release during In-vitro experiments of PPZ-NLCs exhibited a prolonged release profile of the drug best fitted into the Higuchi kinetic model. PPZ-NLCs when examined In-vivo pharmacokinetically a significant increase in t1/2, AUC0-∞, and Cmax was observed which indicates a greater bioavailability and a lesser elimination (Kel). Conclusion: These results suggested the superiority of NLCs in enhancing the bioavailability of PPZ drug and their suitability for successful brain targeting, which could be subject to a patent application to protect the novel formulation.
Nanostructured lipid nanocarrier scaffold of ranolazine: preparation, optimization, in vitro and in vivo evaluations Kiran D. Patil, Yogeeta O. Agrawal Journal of Microencapsulation, 2025 The present study aimed to develop and optimise Ranolazine-loaded Nanostructured Lipid Carriers (RNZ-NLCs) to overcome the poor oral bioavailability and rapid clearance associated with Ranolazine, thereby improving its therapeutic efficacy. RNZ-NLCs were prepared using the hot high-pressure homogenisation technique and optimised using a 2³ factorial design. Characterisation techniques included dynamic light scattering (DLS), differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transform infra-red spectroscopy (FTIR), in vitro drug release profiling, and pharmacokinetic analysis in rats. The optimised RNZ-NLCs exhibited a mean diameter of 205.8 nm, a polydispersity index (PDI) of 0.318, a surface charge (Zeta potential) of -22.4 mV and drug loading of 8.01% w/w. DSC and XRD studies confirmed the transformation of Ranolazine into an amorphous state, and FTIR indicated no chemical interaction with excipients. In vitro release studies showed a sustained release profile, with 65% drug release at 12 hours and 90% at 24 hours, fitting the Korsmeyer-Peppas model. Long-term storage stability studies over 90 days revealed no significant changes in particle characteristics. Pharmacokinetic evaluation in rats showed that RNZ-NLCs increased the Cmax to 18.621 µg/mL (from 9.413 µg/mL for free RNZ), delayed Tmax to 4 h (from 2 h), and enhanced AUC0-∞ to 217.02 µg·h/mL (from 32.06 µg·h/mL). Additionally, mean residence time (MRT) and elimination half-life (t1/2) were extended to 11.83 h and 6.81 h, respectively. RNZ-NLCs significantly improved the pharmacokinetic profile and storage stability of Ranolazine, indicating their potential as a promising delivery system for enhancing oral bioavailability and therapeutic efficacy.
AN UPDATE ON THE ROLE OF ANTIOXIDANTS IN HEALTH AND DISEASE PREVENTION Antioxidants as Nutraceuticals, 2025
IMPORTANCE OF PHYTOCHEMICAL ANTIOXIDANTS Antioxidants as Nutraceuticals, 2025
Mechanistic Understanding of Onychomycosis Progression and Current Advancement in the Transungual Drug Delivery System Gaurav S. Chavan, Aarti Belgamwar, Kiran D. Patil, Yogeeta O. Agrawal Critical Reviews in Therapeutic Drug Carrier Systems, 2025 Onychomycosis, a nail infection prevalent in 50 to 60% of all nail illnesses globally, caused by dermatophytes, poses significant challenges to current therapies due to their limitations in effective administration. This review explores recent advancements in novel drug delivery systems while exploring the molecular mechanisms underlying onychomycosis progression. The physicochemical properties of antifungal treatments and the intricate structure of the nail plate present challenges and can be addressed by nanotechnology-enabled solutions. Furthermore, the review extensively covers diagnostic methods crucial for accurate onychomycosis identification. This review offers insights to enhance onychomycosis management by elucidating mechanistic aspects of the disease. Emphasizing the role of nanotechnology in drug delivery systems, it addresses current treatment challenges using innovative approaches. Moreover, the evaluation of various formulations highlights opportunities to improve therapeutic efficacy. Overall, this comprehensive review explores the current status, challenges, diagnostics advances, and novel approaches for the administration of drugs for the management of onychomycosis.
Design of experiments-based optimization of rutin-loaded nanostructured lipid carriers: characterization, pharmacokinetics, and stability evaluation Shailesh S. Chalikwar, Pratik Mitkari, Kiran D. Patil, Ketan V. Hatware, Meghanath B. Shete Journal of Dispersion Science and Technology, 2025 Due to their minimal toxicity, herbal agents have recently gained preference as therapeutic options for various diseases. However, their clinical efficacy is often restricted due to their physicochemical limitations such as poor aqueous solubility, low bioavailability, and short half-life. This study aimed to develop rutin-loaded nanostructured lipid carriers (Rt-NLCs) to enhance solubility and therapeutic potential. Rt-NLCs were formulated using a high-speed homogenization-ultrasonication technique and optimized through a 3-factorial (3³) Box-Behnken design (BBD). The optimized Rt-NLCs exhibited a particle size (PS) of 172.8 ± 3.10 nm, a polydispersity index (PDI) of 0.32 ± 0.20, a zeta potential (ZP) of −27.2 ± 2.10 mV, and a % entrapment efficiency (EE) of 79 ± 4.31%. The formulation demonstrated sustained drug release (82.12% ± 6.2%) over 30 h compared to a rutin suspension. Transmission electron microscopy (TEM) analysis confirmed that the particles were spherical, smooth-surfaced, and nanosized. Additionally, Rt-NLCs exhibited excellent stability, ensuring an optimal shelf-life. Pharmacokinetic studies revealed a significant increase in bioavailability following intraperitoneal administration of Rt-NLCs compared to the rutin suspension. The findings support the potential of NLC-based encapsulation as a viable method to improve rutin’s therapeutic properties.
IMMUNOMODULATION PROPERTY OF ANTIOXIDANTS Antioxidants as Nutraceuticals, 2025
Advances in Capsaicin-Based Nanocarriers: Bridging Mechanistic Insights with Therapeutic Potential and Clinical Outcomes Kiran Patil, Meghanath B. Shete, Tulshidas S. Patil, Harsh Mahajan, Tejas Mahajan, et al. Assay and Drug Development Technologies, 2025 Capsaicin (CAP), a bioactive compound from chili peppers, possesses a wide range of therapeutic properties, including antiobesity, anticancer, anti-inflammatory, analgesic, and cardioprotective effects. However, its clinical application has been limited due to poor aqueous solubility, low bioavailability, rapid metabolism, and potential side effects with high doses. Recent advancements in nanotechnology have addressed these challenges by enhancing CAP's solubility, stability, and targeted delivery through innovative nanoformulations. This review provides an in-depth analysis of various nanocarrier systems such as solid lipid nanoparticles, nanostructured lipid carriers, liposomes, polymeric nanoparticles, nanoemulsions, and nanocrystals, all of which have demonstrated improved therapeutic efficacy of CAP in preclinical studies. These nanoformulations not only protect CAP from degradation but also enable controlled release, reduce side effects, and improve patient compliance. The therapeutic potential of CAP-loaded nanocarriers has been investigated in a variety of diseases, including cancer, neurodegenerative disorders, and chronic pain, with promising results. This review highlights the latest innovations in CAP nanotechnology and discusses the future directions for clinical applications, paving the way for more effective CAP-based therapies in modern medicine.
A review on Floating Drug Delivery System International Journal of Pharmaceutical Sciences Review and Research, 2013
RECENT SCHOLAR PUBLICATIONS
Advances in capsaicin-based nanocarriers: bridging mechanistic insights with therapeutic potential and clinical outcomes K Patil, MB Shete, T Patil, H Mahajan, T Mahajan, N Maind, R Mehta, ... ASSAY and Drug Development Technologies 24 (2), 85-112 , 2026 2026 Citations: 3
In-vivo Pharmacokinetic Assessment and In-vitro Characterization of Strategically Optimized Perphenazine-loaded Nanostructured Lipid Carriers for Nose-to-brain … YO Agrawal, TS Patil, KD Patil, NA Gujarathi, A Gangwal, SN Goyal Recent Patents on Nanotechnology 20 (2), 167-180 , 2026 2026
Optimizing trifluoperazine delivery for schizophrenia: a quality by design approach to nanostructured lipid carriers with comprehensive in-vitro, pharmacokinetic, and … R Sharma, K Patil, YO Agrawal Journal of Molecular Liquids, 128950 , 2025 2025
Nanostructured lipid nanocarrier scaffold of ranolazine: preparation, optimization, in vitro and in vivo evaluations KD Patil, YO Agrawal Journal of Microencapsulation 42 (6), 623-634 , 2025 2025
Integrated metagenomics and transcriptomics analysis reveals pathways associated with oral periapical lesions formation and progression AM Altaie, T Venkatachalam, K Patil, F Al-Marzooq, SS Rawat, ... Current Research in Microbial Sciences, 100443 , 2025 2025 Citations: 3
Design of experiments-based optimization of rutin-loaded nanostructured lipid carriers: characterization, pharmacokinetics, and stability evaluation SS Chalikwar, P Mitkari, KD Patil, KV Hatware, MB Shete Journal of Dispersion Science and Technology, 1-16 , 2025 2025 Citations: 1
Advancements in bio-resource-based polymers and composites: sustainable alternatives to non-biodegradable plastics for a greener future: A review BK Sharma, A Jha, D Bhalani, SA Pillai, S Pal, K Patil, K Nagaraj Current Green Chemistry , 2025 2025 Citations: 12
Innovative nanostructured lipid scaffolds for Cilnidipine: Design and optimization to elevate the therapeutic potential in hypertensive therapy Y Mali, R Sharma, Y Agrawal, K Patil Journal of Cluster Science 36 (3), 85 , 2025 2025 Citations: 2
Immunomodulation Property of Antioxidants K Patil, S Nangare, M Shete, M Shelke, M Shaikh, M Potdar, V Agnihotri, ... Antioxidants as Nutraceuticals, 95-124 , 2025 2025
Importance of Phytochemical Antioxidants Y Goyal, M Patil, K More, K Patil Antioxidants as Nutraceuticals, 39-65 , 2025 2025 Citations: 1
An update on the role of antioxidants in health and disease prevention MB Potdar, K Patil, MRM Usman, RR Wadekar Antioxidants as Nutraceuticals, 305-336 , 2025 2025 Citations: 4
Mechanistic understanding of onychomycosis progression and current advancement in the transungual drug delivery system GS Chavan, A Belgamwar, KD Patil, YO Agrawal Critical Reviews™ in Therapeutic Drug Carrier Systems 42 , 2025 2025 Citations: 2
THE BEACON 18-12-2024 D Sharma, D Vinodkumar, K Patil MA MCJ , 2024 2024
Quality-by-design-driven nanostructured lipid scaffold of apixaban: optimization, characterization, and pharmacokinetic evaluation K Patil, N Gujarathi, C Sharma, S Ojha, S Goyal, Y Agrawal Pharmaceutics 16 (7), 910 , 2024 2024 Citations: 11
GSK-3α aggravates inflammation, metabolic derangement, and cardiac injury post-ischemia/reperfusion F Ahmad, H Marzook, A Gupta, A Aref, K Patil, AA Khan, MA Saleh, ... Journal of Molecular Medicine 101 (11), 1379-1396 , 2023 2023 Citations: 19
Palm Vein Technology: A Biometric Intelligence System for patients Authentication and Safety SB Bagade, KD Patil, KV Hatware, PL Pingale, SVC Mhatre Research Journal of Pharmacy and Technology 16 (11), 5554-5561 , 2023 2023 Citations: 1
Nicotinamide riboside kinase-2 regulates metabolic adaptation in the ischemic heart H Marzook, A Gupta, D Tomar, MA Saleh, K Patil, MH Semreen, ... Journal of Molecular Medicine 101 (3), 311-326 , 2023 2023 Citations: 16
Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment YO Agrawal, KD Patil, KR More, MUM Siddique, S Alkahtani, NH Aljarba, ... Journal of drug delivery science and technology 77, 103894 , 2022 2022 Citations: 10
Development of Carmustine Loaded PLGA-PEG Conjugates for Nose to Brain Targeting. MB Potdar, NK Jain, KD Patil, YS Goyal Indian Journal of Pharmaceutical Education & Research 56 (4) , 2022 2022 Citations: 5
Verapamil hydrochloride loaded solid lipid nanoparticles: Preparation, optimization, characterisation, and assessment of cardioprotective effect in experimental model of … YO Agrawal, M Husain, KD Patil, V Sodgir, TS Patil, VV Agnihotri, ... Biomedicine & Pharmacotherapy 154, 113429 , 2022 2022 Citations: 31
MOST CITED SCHOLAR PUBLICATIONS
Natural anti-obesity agents and their therapeutic role in management of obesity: A future trend perspective S Karri, S Sharma, K Hatware, K Patil Biomedicine & Pharmacotherapy 110, 224-238 , 2019 2019 Citations: 262
Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities K Patil, S Bagade, S Bonde, S Sharma, G Saraogi Biomedicine & pharmacotherapy 99, 735-745 , 2018 2018 Citations: 108
Evidence for gastroprotective, anti-inflammatory and antioxidant potential of methanolic extract of Cordia dichotoma leaves on indomethacin and stress induced gastric lesions … KV Hatware, S Sharma, K Patil, M Shete, S Karri, G Gupta Biomedicine & Pharmacotherapy 103, 317-325 , 2018 2018 Citations: 103
Rosmarinic acid attenuates inflammation in experimentally induced arthritis in Wistar rats, using Freund’s complete adjuvant RK Gautam, G Gupta, S Sharma, K Hatware, K Patil, K Sharma, S Goyal, ... International journal of rheumatic diseases 22 (7), 1247-1254 , 2019 2019 Citations: 72
The toxicological effects of lead and its analytical trends: an update from 2000 to 2018 ES Ravipati, NN Mahajan, S Sharma, KV Hatware, K Patil Critical reviews in analytical chemistry 51 (1), 87-102 , 2021 2021 Citations: 49
Verapamil hydrochloride loaded solid lipid nanoparticles: Preparation, optimization, characterisation, and assessment of cardioprotective effect in experimental model of … YO Agrawal, M Husain, KD Patil, V Sodgir, TS Patil, VV Agnihotri, ... Biomedicine & Pharmacotherapy 154, 113429 , 2022 2022 Citations: 31
In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach Y Agrawal, K Patil, H Mahajan, M Potdar, P Joshi, K Nakhate, C Sharma, ... Drug Delivery 29 (1), 1112-1121 , 2022 2022 Citations: 31
Role of herbal medicine in the Management of Urolithiasis—A Review for future perspectives A Patle, KV Hatware, K Patil, S Sharma, G Gupta Journal of Environmental Pathology, Toxicology and Oncology 38 , 2019 2019 Citations: 30
Kinetics studies on esterification reaction of acetic acid with iso-amyl alcohol over ion exchange resin as catalysts KD Patil, BD Kulkarni Int J Eng Res 3 (8), 488-93 , 2014 2014 Citations: 28
In-vitro and ex-vivo characterization of novel mannosylated gelatin nanoparticles of linezolid by quality-by-design approach KD Patil, SB Bagade, SC Bonde Journal of Drug Delivery Science and Technology 60, 101976 , 2020 2020 Citations: 22
GSK-3α aggravates inflammation, metabolic derangement, and cardiac injury post-ischemia/reperfusion F Ahmad, H Marzook, A Gupta, A Aref, K Patil, AA Khan, MA Saleh, ... Journal of Molecular Medicine 101 (11), 1379-1396 , 2023 2023 Citations: 19
Potential of herbal constituents as new natural leads against helminthiasis: A neglected tropical disease KD Patil, SB Bagade, SR Sharma, KV Hatware Asian pacific journal of tropical medicine 12 (7), 291-299 , 2019 2019 Citations: 19
Nicotinamide riboside kinase-2 regulates metabolic adaptation in the ischemic heart H Marzook, A Gupta, D Tomar, MA Saleh, K Patil, MH Semreen, ... Journal of Molecular Medicine 101 (3), 311-326 , 2023 2023 Citations: 16
QbD-enabled stability-indicating assay method for the estimation of linezolid in newly developed gelatin nanoparticles for anti-tubercular therapy KD Patil, SB Bagade, SC Bonde Chromatographia 83 (8), 963-973 , 2020 2020 Citations: 15
Biodistribution, pharmacokinetics and toxicity evaluation of mannosylated gelatin nanoparticles of linezolid for anti-tubercular therapy KD Patil, SB Bagade, SC Bonde Materials Technology 37 (2), 95-103 , 2020 2020 Citations: 13
Advancements in bio-resource-based polymers and composites: sustainable alternatives to non-biodegradable plastics for a greener future: A review BK Sharma, A Jha, D Bhalani, SA Pillai, S Pal, K Patil, K Nagaraj Current Green Chemistry , 2025 2025 Citations: 12
Quality-by-design-driven nanostructured lipid scaffold of apixaban: optimization, characterization, and pharmacokinetic evaluation K Patil, N Gujarathi, C Sharma, S Ojha, S Goyal, Y Agrawal Pharmaceutics 16 (7), 910 , 2024 2024 Citations: 11
Review of contractor prequalification criteria and their impact on project success factors S Patil, B Konnur, P Devthanekar, K Patil International Journal of Research in Engineering, Science and Management 3 … , 2020 2020 Citations: 11
Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment YO Agrawal, KD Patil, KR More, MUM Siddique, S Alkahtani, NH Aljarba, ... Journal of drug delivery science and technology 77, 103894 , 2022 2022 Citations: 10
Review on chemistry, analysis and pharmacology of Teneligliptin: A novel DPP-4 inhibitor S Sharma, R Sharma, K Hatware, K Patil Mini Reviews in Medicinal Chemistry 20 (12), 1091-1100 , 2020 2020 Citations: 8